{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 25 of 92', 'CR845-CLIN3103', '1.5 mcg/kg, n=44) or placebo (n=45) administered at the end of each dialysis session', '(ie, 3 times/week). The primary efficacy endpoint for Study CR845-CLIN2101 was', 'based on itch intensity measurement and defined as the change from a 1-week baseline', 'recorded prior to the start of study drug to the last week of the 8-week treatment period', 'with respect to the weekly mean of the daily 24-hour Worst Itching Intensity numerical', 'rating scale (NRS) score. The least squares (LS) mean (standard error [SE]) treatment', 'group difference from placebo at Week 8 across all CR845 doses was - -1.3 (=0.41) (95%', 'confidence interval [CI]: -2.1 to -0.5) (p=0.002) with an average NRS score reduction', 'from baseline of -3.2 (+0.22) (LS mean SE) and 95% CI ranging from -3.7 to -2.8.', 'Examination of the individual CR845 dose group results for the Full Analysis Population', 'indicates that a substantial improvement over placebo was observed with all 3 doses.', 'These differences from placebo were statistically significant for the lower dose group of', '0.5 mcg/kg (p<0.001) and the 1.5 mcg/kg group (p=0.019), with an effect size estimated', 'as 0.82, 0.39, and 0.62 for the 0.5, 1.0, and 1.5 mcg/kg doses, respectively. Average', 'reduction from baseline (LS mean SE) ranged from -2.8 (+0.38) in the 1.0 mcg/kg dose', 'group (95% CI ranging from -3.5 to -2.0) to -3.8 (=0.38) in the 0.5 mcg/kg dose group', '(95% CI ranging from -4.5 to - -3.1).', '4.2.4', 'Pharmacokinetics in Hemodialysis Patients', 'CR845 is eliminated primarily through the kidney and no major metabolites have been', 'identified in humans. Consequently, total body clearance of CR845 in patients with', 'severe renal impairment is reduced relative to healthy, matched, control patients', '(CR845-CLIN1005) such that plasma levels of CR845 remain relatively constant until', 'cleared during dialysis in hemodialysis patients (CR845-CLIN1003 and', 'CR845-CLIN2005 [Part A]). Half-life ranges between 26 and 34 hours in hemodialysis', 'patients compared to a typical range of 2 to 3 hours in patients with normal renal', 'function. Thus, lower doses of CR845 can be administered at a less frequent interval in', 'hemodialysis patients to achieve the same or higher overall exposure compared to', 'individuals with normal renal function. Based on this pharmacokinetic profile, CR845', 'does not need to be administered more than 3 times a week after each hemodialysis', 'session, which is convenient for this patient population and ensures treatment compliance', 'in a population already burdened with complex medication schedules.', 'The pharmacokinetic profile of repeat-dose CR845 was studied in 24 hemodialysis', 'patients who received doses of 0.5, 1.0, or 2.5 mcg/kg 3 times per week for 1 week', '(CR845-CLIN2005 [Part A]). In this study, there were dose-proportional increases in', 'maximum concentration and area under the curve, and minimal to no accumulation with', \"repeat doses due to clearance of the drug by hemodialysis (see Investigator's Brochure\", 'for details).', '4.3', 'Summary of Potential Risks and Benefits', 'During preclinical development, no specific safety findings to preclude the use of CR845', 'in humans were observed. During early clinical development, IV CR845 was', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 26 of 92', 'CR845-CLIN3103', 'administered to healthy volunteers; patients with mild, moderate, or severe renal', 'impairment, including end-stage renal disease (ESRD) and hemodialysis patients;', 'recreational poly-drug users; and postsurgical patients. The effects of CR845 have been', 'shown to be in line with the underlying pharmacological mechanism of KOR activity.', 'Consistent with the nonclinical abuse liability studies conducted to date, the results of an', 'abuse-potential study in humans indicated that CR845 appears to present a low risk for', 'abuse potential in humans in comparison to currently clinically used opioids.', 'Overall, tingling/numbness, dizziness, fatigue and/or drowsiness/somnolence have been', 'the most common adverse events. Precaution is recommended in the operation of', 'machinery for patients who experience dizziness, fatigue, and/or drowsiness/somnolence.', 'This is described in the informed consent form (ICF), as appropriate, and will be', 'discussed with each patient prior to initiation of the study. In general, CR845 appeared to', 'be generally well tolerated in both single- and repeat-dose clinical studies in hemodialysis', 'patients, which support continued study and development of this compound.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}